Alternative routes to human data: longevity companies search for a way around the regulatory deadlock
The cost of testing an experimental treatment in humans has risen so steeply that many promising longevity interventions never make it to the clinic. A growing number of companies are now looking for creative, legal workarounds -- and that is reshaping how aging research develops.
A Phase 1 clinical trial in the US or Europe can easily run into tens of millions of euros, and that is before you have demonstrated any efficacy at all. The extensive safety data that regulators require, combined with the sheer logistics of recruiting participants, puts the bar far too high for small companies and academic groups. The problem is especially acute in the longevity sector, where many of the most promising candidates are relatively cheap existing molecules or early-stage biological preparations.
Mitrix Bio is one of the companies held up as an example in this piece. It is working on mitochondrial therapies -- treatments designed to repair or strengthen the energy-generating machinery inside cells -- which are relevant to a wide range of aging-related conditions. Rather than follow the standard regulatory path, the company is exploring alternatives: Right to Try legislation in the US (which gives terminally ill patients access to unapproved treatments), trials in countries with different regulatory frameworks, and expanded access programs.
Learning faster, but at what cost?
The logic is understandable. When an intervention is tested in seriously ill or dying patients under Right to Try, it generates the first human signals without the full regulatory burden. That data can then be used to persuade investors and fund formal trials. It is not a substitute for controlled clinical studies, but it can serve as a first step that would otherwise be financially out of reach.
The downsides are real, though. Data gathered outside controlled settings are hard to interpret. Placebo effects, patient selection bias, and the absence of a control group make it genuinely difficult to separate true efficacy from noise. There are ethical questions too: are vulnerable patients adequately protected when they are treated with unproven therapies outside formal trials? Critics point out that the approach sometimes functions more as a marketing tool than as a scientific method.
A structural problem at the heart of the field
What this story exposes is a structural mismatch between the time horizons of aging research and the funding logic of biotech. Aging is a slow process; trials that want to say something meaningful about lifespan or healthspan are extraordinarily expensive and take a very long time. The pressure to work faster, cheaper, and more flexibly is genuine, but the scientific standards that protect the quality of human data exist for good reason. How you resolve that tension is one of the most urgent questions facing the field.